Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines

Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to develop novel therapeutics beyond vaccines.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Industry

Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, aiming to develop novel therapeutics beyond vaccines.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at GEN — Genetic Engineering & Biotechnology News.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines | Brilliant Blue Biosciences